Research programme: NMDA receptor antagonists - Neurotune

Drug Profile

Research programme: NMDA receptor antagonists - Neurotune

Alternative Names: BND-003; BND-13317; BND-3; NiK 003; Nik-003; NiK-13317; NT-13317; NT-24336

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator NiKem Research
  • Developer Neurotune
  • Class Lactams
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetic neuropathies; Neuropathic pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in Switzerland (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-neuropathies in Switzerland
  • 03 Nov 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the adverse events and Pain pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top